Abstract: Tumor necrosis factor (TNF)-a inhibitors (anti-TNF-a
INTRODUCTION
Tumor necrosis factor-a (TNF-a) is a proinflammatory cytokine produced by a variety of cells including keratinocytes, Langerhans cells, and activated T lymphocytes.
1,2 TNFa is believed to play a critical role in the pathogenesis of inflammatory and autoimmune conditions such as rheumatoid arthritis, Crohn disease, and psoriasis. [1] [2] [3] [4] [5] [6] Thus, TNF-a inhibitors (anti-TNF-a biologic drugs) have become important agents in the treatment of such diseases. The 3 anti-TNF drugs most commonly used to treat rheumatoid arthritis and other inflammatory conditions are infliximab, adalimumab, and etanercept. Infliximab is a chimeric (three-quarters human and one-quarter mouse) anti-TNF monoclonal antibody, adalimumab is a human anti-human TNF monoclonal antibody, and etanercept is a fusion protein that links human TNF receptor 2 and the Fc component of human immunoglobulin G1. 4, 5 These biologic drugs bind TNF and block its access to TNF receptors on the surface of target cells, thereby preventing inflammation and tissue damage. 5 However, these biologic drugs may be associated with various adverse reactions including cutaneous reactions. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In addition to the paradoxical worsening of skin lesions in some patients with preexisting psoriasis, clinical lesions identical to psoriasis have been reported in patients with no personal or family history of psoriasis. Although there are reports documenting such cases, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] the histopathology of anti-TNF-a inhibitor-induced skin reactions remains to be characterized in a systematic fashion. The present study was conducted to determine the spectrum of histopathologic changes in patients who developed a clinically ''psoriasiform'' eruption while receiving anti-TNF-a inhibitors for the treatment of autoimmune diseases other than psoriasis.
MATERIALS AND METHODS
This study was approved by our Institutional Review Board. Nine patients on anti-TNF therapy for different autoimmune diseases, who developed a scaly erythematous to pustular ''psoriasiform'' skin eruption, were identified from the files of the Department of Dermatology, Brigham and Women's Hospital. Subsequently, the corresponding skin biopsies were retrieved from the Department of Pathology. None of these patients had prior history of psoriasis or lichen planus. Relevant clinical data were recorded for each patient including age, sex, diagnosis, anti-TNF-a agent, clinical diagnosis of skin adverse reaction, treatment of adverse reaction, and outcome. The following histopathologic parameters were recorded for all specimens: general reaction pattern, composition of the inflammatory infiltrate, and presence and number of eosinophils and plasma cells. A semiquantitative scale was used to quantify eosinophils and plasma cells as follows: not identified = none; #1/5 high power field (HPF) = scattered; and .1/5 HPF = numerous.
RESULTS
Sixteen biopsies from 9 patients were included in the study. Table 1 summarizes the demographic and correlative clinical-pathological data of all 9 patients. All but one patient were females. The mean age at presentation was 51 years. The most common diagnosis for which anti-TNF-a therapy was prescribed was rheumatoid arthritis (n = 7). The remaining 2 patients had a diagnosis of Crohn disease and Behc xet disease, respectively. Patients presented to dermatology for a papulosquamous to pustular eruption appearing from 2 to 12 months after initiation of anti-TNF-a therapy. Clinical impressions can be found in Table 1 . It is noteworthy that some patients had several lesions with similar or different morphological features, either simultaneously or temporally, and therefore had more than 1 biopsy. Of 16 biopsies, 10 showed a psoriasiform pattern, 4 showed a lichenoid/interface pattern, and 2 showed a neutrophil-rich inflammatory infiltrate predominantly involving hair follicles. Amongst the 10 biopsies with psoriasiform morphology, 4 showed features mimicking eruptive/guttate psoriasis, 3 showed features of well-established plaques of psoriasis, and 3 mimicked pustular psoriasis. Guttate-like lesions showed mild irregular epidermal hyperplasia with minimal spongiosis and hypogranulosis associated with mounds of parakeratosis containing neutrophils (Fig. 1) . There was also papillary dermal edema with dilated blood vessels in these cases (Fig. 1) . The superficial inflammatory infiltrate was predominantly lymphocytic with no eosinophils or plasma cells (1 case), scattered eosinophils and plasma cells (2 cases), and numerous eosinophils and no plasma cells (1 case). Plaque-like lesions showed regular psoriasiform epidermal hyperplasia with hypogranulosis associated with confluent parakeratosis containing aggregates of neutrophils (Fig. 2 ). There was papillary dermal edema and prominent blood vessels in all cases. The infiltrate varied from superficial to superficial and mid and was composed of lymphoid cells and scattered neutrophils in all cases. In addition to lymphoid cells and neutrophils, there were scattered eosinophils and plasma cells in 2 cases and numerous eosinophils and plasma cells in 1 case. Pustular psoriasiform lesions showed a subcorneal and superficial intraepidermal spongiform pustule containing numerous neutrophils associated with parakeratosis ( Fig. 3 ). There were papillary dermal edema and tortuous blood vessels in all cases. The epidermis adjacent to the pustule was minimally hyperplastic in 2 cases and showed psoriasiform hyperplasia in 1 case. In addition to lymphoid cells and neutrophils, the superficial to mid-dermal infiltrate had scattered eosinophils and plasma cells in 1 case, numerous eosinophils with scattered plasma cells in 1 case, and numerous eosinophils and plasma cells in another case ( Table 2 ). The 4 lichenoid lesions were characterized by epidermal hyperplasia with saw-tooth appearance associated with vacuolar alteration of the basal cell layer and numerous eosinophilic cytoid bodies (Figs. 4-6 ). There were foci of wedge-shaped hypergranulosis and predominantly orthokeratosis. All cases showed focal parakeratosis (Fig. 6 ). There was a dense band-like lymphoid infiltrate with scattered melanophages in all cases. In addition to the band-like superficial infiltrate, there was a perivascular mid to deep dermal infiltrate in all cases (Figs. 4 , 5B). Eosinophils varied from none (1 case), to scattered (1 case) to numerous (2 cases). Plasma cells were numerous in all cases ( Fig. 5B and Table 2 ). In the 2 cases of pustular folliculitis, there was a suppurative neutrophilic infiltrate involving the follicular epithelium (Fig. 7) . One of these biopsies showed scattered eosinophils and plasma cells and the other showed numerous eosinophils and plasma cells. Diastase-PAS was negative in all 16 cases. A Steiner stain was performed in all cases containing plasma cells in the infiltrate and they were negative for spirochetes. All pustular lesions had negative cultures. The majority of patients improved with topical treatment without the need to discontinue the anti-TNF drug. Four patients improved only after the anti-TNF drug was stopped. In 2 cases, the lesions reappeared after anti-TNF therapy was restarted even when switching to a different anti-TNF drug.
DISCUSSION
TNF-a has pleiotropic functions that include Langerhans cell maturation, keratinocyte proliferation, and increased expression of vascular endothelial adhesion molecules and growth factors.
1,3 TNF-a is believed to play a critical role in the pathogenesis of inflammatory and autoimmune diseases. [1] [2] [3] [4] [5] [6] Thus, TNF-a inhibitors have become important agents in the treatment of moderate to severe cases of autoimmune diseases such as rheumatoid arthritis, Crohn disease, and psoriasis. Anti-TNF-a biologic drugs consist of human-mouse chimeric antibodies (eg, infliximab), human monoclonal antibodies (eg, adalimumab), and TNF-receptor fusion proteins (eg, etanercept) that bind TNF, blocking its access to TNF receptors on the surface of target cells. 4, 5 Although not completely understood, studies have shown that the mechanism of action of anti-TNF-a biologic medication involves the reduction of multiple proinflammatory cytokines such as interleukin-1 and interleukin-6, and other inflammatory molecules such as C-reactive protein, serum amyloid A, and haptoglobin. 17 Other studies have suggested that these drugs affect cell trafficking as evidenced by altered cell recruitment into joints after treatment, 18 and that blockade of TNF-a diminishes angiogenesis and reduces levels of metalloproteinases MMP1 and MMP3. 19 Anti-TNF drugs are currently commonly and successfully used in the treatment of several autoimmune conditions. However, as these agents have gained more widespread use in the treatment of these conditions, the number and variety of skin reactions has also increased. A variety of cutaneous reactions such as psoriasiform, lichenoid, eczematous, erythema multiforme-like, lupus erythematosuslike, granulomatous, vasculitic, and pseudolymphomatous have been reported. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [20] [21] [22] The pathogenesis of anti-TNF-induced psoriasis is poorly understood but it appears that interferon-a (IFN-a) may be involved. Plasmacytoid dendritic cells appear capable of inducing psoriasis via production of interferon-a. IFN-a plays a key role in early stages of psoriasis and its production by plamacytoid dendritic cells is normally downregulated by TNF. This is a possible operant mechanism in patients with untoward reactions to these molecules because TNF-a is known to inhibit plasmacytoid dendritic cell maturation from hematopoietic precursors. 4, 5 Blockage of TNF by anti-TNF drugs may lead to uncontrolled production of IFN-a and may cause the onset and or worsening of psoriasiform lesions.
The new onset or worsening of skin lesions typical of psoriasis at any time after initiation of anti-TNF-a blocker therapy is becoming increasingly recognized. There are several clinical cases reported in the literature to date, and this adverse reaction has been observed with almost every condition treated with TNF-a biologic drugs. 1, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 20 However, only a minority of these studies include histopathologic descriptions of such psoriasiform lesions, and when available, these tend to be brief and lesions are usually described as histopathologically indistinguishable from psoriasis. We present here the histopathologic spectrum of papulosquamous and pustular drug eruptions elicited during anti-TNF-a therapy, as observed in 9 patients. The histopathologic spectrum included a pattern closely mimicking psoriasis (early/guttate, well-established/ plaque, and pustular), a lichenoid pattern reminiscent of lichen planus and an unusual sterile pustular folliculitis. Multiple reaction patterns (eg, guttate, plaque, pustular, and folliculitis) could be found in individual patients, either concurrently or temporally. The psoriasiform pattern closely mimicked psoriasis in a few cases in which eosinophils were very rare or absent. More frequently, variable numbers of eosinophils and plasma cells could be identified, and these features can be of help in distinguishing such drug reactions from primary psoriasis. In the lichenoid reactions, focal mounds of parakeratosis and a deeper inflammatory infiltrate with a variable number of eosinophils and numerous plasma cells were present in all cases; these features should alert the pathologist of the most likely possibility of a lichenoid hypersensitivity reaction and not primary lichen planus. It is noteworthy that these histologically lichenoid cases also presented with ''psoriasiform'' features clinically and the favored clinical diagnosis was psoriasis. Perhaps, the consistent presence of parakeratosis in these drug-related lichenoid cases, which is unusual in lichen planus, and characteristic in psoriasis, could explain this clinical presentation. We could not find reported cases of sterile pustular folliculitis associated with anti-TNF therapy. However, there are reports of acneiform eruptions associated with such drugs and it is possible that they represent the same process we are describing. 23 Our cases of pustular folliculitis were seen in patients with extensive lesions mimicking psoriasis, from guttate to plaque to pustular. One of our patients (case 4; see Table 1 ) was a 61-year-old woman with rheumatoid arthritis who presented for a papular and pustular rash involving the back of the neck, trunk, and extremities that started a few months after initiating anti-TNF therapy. The first biopsy showed features of pustular folliculitis (Fig. 7) . These lesions evolved to larger scaly plaques involving the trunk and extremities and a second biopsy showed features similar to those seen in plaque lesions of psoriasis (Fig. 2) . In time, the lesions became pustular plaques and a third biopsy was consistent with pustular psoriasis-like drug eruption (Fig. 4) . Taking into consideration the clinical presentation, we believe that the folliculocentric pustular reaction most likely represents one end of the spectrum of the pustular ''psoriasiform'' lesions in patients on anti-TNF therapy. All the pustular lesions in our series had negative microbiological cultures. The presence of eosinophils in the infiltrate in conjunction with the clinical history and negative special stains and cultures aided in establishing the diagnosis in what otherwise resembled an infectious pustular folliculitis. It is important to keep in mind, however, that this patient population is frequently immunosuppressed, either by their disease process or by their medication regimen, and when they present with pustular lesions, special stains and cultures are mandatory to rule out infection.
The contributing factors and precise mechanism by which this new class of therapeutic agents causes psoriasiform and papulosquamous skin lesions remain to be elucidated. All TNF-a antagonists have been associated with adverse cutaneous reactions, particularly those of psoriasiform nature, which suggests a common cytokine dysregulation consequent to TNF-a blockade. In keeping with our findings, the majority of reported patients relapsed when switched to a different TNF-a inhibitor, suggesting a drug class effect rather than an idiosyncratic and specific reaction to certain drugs in particular patients. 7 The observation that certain patients can be successfully treated by switching to a different anti-TNF-a agent suggests that idiosyncratic reactions can also occur in a minority of patients. In summary, we described the histopathologic spectrum observed in 16 biopsies from 9 patients who presented with a clinically ''psoriasiform'' skin reaction in the setting of anti-TNF-a therapy. Such reactions may mimic primary dermatitis such as psoriasis and lichen planus on clinical and morphological grounds. The presence of eosinophils and plasma cells in the majority of these biopsies seems to be an important clue to distinguish them from primary dermatitis. Furthermore, lichen-planus like lesions showed focal parakeratosis and an infiltrate that was deeper than usually seen in typical lichen planus. The distinguishing features, however, may be subtle and eosinophils and plasma cells may be absent or rare in a minority of cases, clinical correlation is crucial for accurate diagnosis in such cases. An unusual form of sterile pustular folliculitis that is likely to be part of the spectrum of pustular psoriasiform lesions was also observed and should be included in the list of skin reactions associated to these drugs.
